High-dose versus weekly cisplatin definitive chemoradiotherapy for HPV-related oropharyngeal squamous cell carcinoma of the head and neck

An estimated 500,000 new squamous cell carcinoma of the head and neck (SCCHN) patients are diagnosed every year worldwide and in the United States (US) more than 13,000 deaths are expected due to SCCHN in the year 2016 alone [1]. SCCHN is often categorized into two main subgroups depending on their association with human papillomavirus (HPV). This risk stratification is clinically important since HPV-negative SCCHN carries a poor prognosis when compared with HPV-associated tumors [2]. During the last two decades there has been a significant increase in the overall incidence of oropharyngeal cancer (OPC) around the world and in the US.

http://ift.tt/2kqJyIS